Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 33, Issue 3, 2016, Pages 224-234

  Doubková, Martina ^a   Karpíšek, Michal ^b   Mazoch, Jiří ^b   Skřičková, Jana ^a   Doubek, Michael ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b Analytical Testing Service   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chronic pulmonary obstructive disease; Clara cell protein 16; Idiopathic pulmonary fibrosis; Prostatic secretory protein 94; S100 protein; Sarcoidosis; Surfactant protein A; Surfactant protein D; Trefoil factor 3

Indexed keywords

BIOLOGICAL MARKER; CALCYCLIN; CLARA CELL PROTEIN; PROSTATIC SECRETORY PROTEIN; PROTEIN CC16; PROTEIN PSP94; PROTEIN S 100; PROTEIN S100A11; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; BETA-MICROSEMINOPROTEIN; SCGB1A1 PROTEIN, HUMAN; TFF3 PROTEIN, HUMAN; UTEROGLOBIN;

ADULT; AGED; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FUNCTION TEST; LUNG INTERSTITIUM; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SPIROMETRY; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC SECRETORY PROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; S100 PROTEINS; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED; TREFOIL FACTOR-3; UTEROGLOBIN;

EID: 85015352761     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic Pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6): 788-824.
3. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16(2): 149-73.
4. Global initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013; http: //www.goldcopd. org/uploads/users/files/GOLD-Report2014-Feb07.
5. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Pro Am Thorac Soc 2006; 3(4): 364-372.
6. Madsen J, Kliem A, Tornoe I, Skjodt K, Koch C, Holmskov U. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000; 164(11): 5866-70.
7. Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy 2000; 30(4): 469-75.
8. Moore BW. A soluble protein characteristic of the nervous system Biochem Biophys Res Commun 1965; 19(6): 739-44.
9. Zimmer DB, Conwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37(4): 417-29.
10. Kamada M, Mori H, Maeda N, et al. Beta-microseminoprotein/prostatic secretory protein is a member of immunoglobulin binding factor family. Biochim Biphys Acta 1998; 1388(1): 101-10.
11. Ulvsbaeck M, Lindstroem C, Weiber H, Abrahamsson PA, Lilja H, Lundwall A. Molecular cloning of a small prostate protein, known as beta-microseminoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun 1989; 164(3): 1310-5.
12. Ohkubo I, Tada T, Ochiai Y, Ueyama H, Eimoto T, Sasaki M. Human seminal plasma β-microseminoprotein: its purification, characterization, and immunohistochemical localisation. Int J Biochem Cell Biol 1995; 27(6): 603-11.
13. Graness A, Chwieralski CE, Reinhold D, Thim L, Hoffmann W. Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-Alpha-induced interleukin-6 (IL-6) and IL-8 secretion. J Biol Chem 2002; 277(21): 8440-6.
14. Qu Y, Yang Y, Ma D, Xiao W. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncology reports 2012; 27(4): 1277-83.
15. dos Santos Silva E, Ulrich M, Döring G, Botzenhart K, Gött P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000; 190(2): 133-42.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26(2): 319-38.
17. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26(3): 511-22.
18. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26(4): 720-35.
19. Gay S, Kazerooni E, Toews G, et al. Idiopathic pulmonary fibrosis. Predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157 (4 Pt 1): 1063-72.
20. Huang HB, Peng XN, Nakajima J. Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends 2013; 7(4): 172-7.
21. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19(3): 439-46.
22. Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 2012; 142(4): 1027-34.
23. Kunitake R, Kuwano K, Yoshida K, et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration 2001; 68(5): 488-95.
24. Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Difuse Lung Dis 2009; 26(2): 155-61.
25. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152(6 Pt 1): 1860-66.
26. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135(6): 1557-63.
27. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013; 143(5): 1422-9.
28. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000; 162 (3 Pt 1): 1109-14.
29. Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S. Monitoring markers of disease activity for interstitial lung disease with serum surfactant proteins A and D. Respirology 2006; 11 Suppl: S51-4.
30. Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med 2012; 106(4): 571-80.
31. More JM, Voelker DR, Silveira LJ, Edwards MG, Chan ED, Bowler RP. Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease. BMC Pulm Med 2010; 10: 53.
32. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 2011; 12: 29.
33. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6(6): 543-5.
34. Sin DD, Lejny R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: A pilot study. BMC Pulm Med 2007; 7: 13.
35. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008; 63(12): 1058-63.
36. Emami S, Rodrigues S, Rodrigue CM, et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004; 25(5): 885-98.
37. Vancheri C. Idiopathic pulmonary fibrosis: An altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 2012; 9(3): 153-7.